2014-12-02 21:02:30 UTC

Probiotic VSL#3 Reduces Liver Disease Severity and Hospitalization in Patients With Cirrhosis

Dec. 4, 2014

Reporting in Gastroenterology, Radha K. Dhiman and colleagues find that, over a six-month period, daily intake of the probiotic VSL#3 significantly improved liver function and reduced the risk of hospitalization for hepatic encephalopathy (HE).

Little is known about whether probiotics can affect outcomes of patients with cirrhosis and hepatic encephalopathy (HE). Radha K. Dhiman and colleagues assessed the efficacy of a probiotic preparation in preventing the recurrence of HE (primary outcome) and reducing the number of hospitalizations and severity of liver disease in patients with cirrhosis. Reporting in Gastroenterology, they find that, over a six-month period, daily intake of VSL#3 significantly reduced the risk of hospitalization for HE, as well as Child–Turcotte–Pugh and model for end-stage liver disease scores, in patients with cirrhosis.

Gastroenterology 2014: 147(6): 1327-1337.e3

More on Cirrhosis

Blog: Special 15th Anniversary Collection from Clinical Gastroenterology and Hepatology

Oct. 11, 2017

Celebrate this milestone with a look back at landmark articles, commentaries and reviews. Read more on the AGA Journals blog.

Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis

Oct. 11, 2017

Statin use is probably associated with lower risk of hepatic decompensation and mortality, and might reduce portal hypertension, in patients with CLDs.

Cirrhosis Presenting as Cutaneous Calciphylaxis

Oct. 11, 2017

A 73-year-old woman with a history of hypertension presented with a 3-month history of a painful, non-healing right calf ulcer and 2–3 weeks of painful, dusky purple patches on the right thigh.